https://pmc.ncbi.nlm.nih.gov/articles/PMC11647608/
Efficacy, safety, and quality of life 4 years after valoctocogene roxaparvovec gene transfer for...
Valoctocogene roxaparvovec, an adeno-associated virus-mediated gene therapy for severe hemophilia A, enables endogenous factor (F)VIII expression and provides...